Teva Pharmaceutical Industries TEVA bankruptcy news

Questions investors ask

Legal and investor matters

Checked against Teva Pharmaceutical Industries filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

1. Sep 16, 2026Financing

   Teva subsidiaries issue euro and dollar senior notes on 2026-09-16

   On 2026-09-16 three Teva finance subsidiaries issued senior notes: 1.0 billion euros of 4.250% notes due 2033, 500 million euros of 4.625% notes due 2036, and US dollar notes of 1.0 billion due 2034, 1.0 billion due 2037 and 1.2 billion due 2032. Teva said net proceeds would fund redemptions of certain existing notes, fees, and general corporate purposes, including repaying debt.

   Teva 8-K filed 2026-09-16

2. Sep 14, 2026Governance

   Teva ordinary shares begin trading on NYSE as ADS program ends

   Teva began trading its ordinary shares on the New York Stock Exchange on 2026-09-14 in place of its American depositary shares, under the same ticker TEVA. The ADS program terminated that day and each ADS was exchanged for one ordinary share. The shares continue to trade on the Tel Aviv Stock Exchange. An amendment to the deposit agreement dated 2026-08-31 provided for the mandatory exchange.

   Teva 8-K filed 2026-09-14

3. Jul 29, 2026Class action

   Teva reaches agreement in principle in Copaxone securities class action

   Teva's 10-Q filed July 29, 2026 says that in May 2026 the parties to a putative securities class action in the Eastern District of Pennsylvania reached an agreement in principle to resolve the case. The amended complaint alleges that Teva and certain current and former officers violated federal securities laws by allegedly making false and misleading statements about Copaxone, including by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through donations to charities. The putative class period is October 29, 2015 to August 18, 2020. Teva recognized a provision in the second quarter of 2026, a portion of which is expected to be covered by insurance.

   U.S. District Court, Eastern District of Pennsylvania · Status: pending

   Teva 10-Q for the quarter ended 2026-06-30

4. Jul 29, 2026Litigation

   Generic drug price-fixing litigation: Teva reaches deals with indirect resellers

   Teva reported that as of July 2026 all manufacturer defendants, including Teva and Actavis, reached agreements in principle to settle the indirect reseller plaintiffs' claims in the generic drug multidistrict litigation in the Eastern District of Pennsylvania. The December 2026 trial is no longer expected. Teva recorded provisions in the second quarter of 2026. The complaints allege price fixing and market allocation. Claims by state attorneys general and opt-out plaintiffs remain pending.

   U.S. District Court, Eastern District of Pennsylvania (MDL) · Status: pending

   Teva 10-Q for the quarter ended 2026-06-30

5. Jun 13, 2026Litigation

   Court preliminarily approves Teva opioid settlement with third-party payers

   Teva's 10-Q filed July 29, 2026 says that on 2026-06-13 the court in the opioid multidistrict litigation in the Northern District of Ohio granted preliminary approval to Teva's settlement with a class of third-party payers and scheduled a fairness hearing for 2026-09-23. Teva reached the agreement in principle in the first quarter of 2026. The settlement is contingent on Teva's satisfaction, in its sole discretion, with the level of participation by the third-party payers. The filing says Teva has recorded a provision for its opioid settlements.

   U.S. District Court, Northern District of Ohio (MDL) · Status: pending

   Teva 10-Q for the quarter ended 2026-06-30

6. May 26, 2026Regulatory

   Government declines to intervene in qui tam over former Irvine plant

   On 2026-05-26 the government notified the U.S. District Court for the District of Massachusetts of its decision not to intervene in a False Claims Act qui tam complaint filed under seal by a former employee. The complaint was unsealed on 2026-05-27, and the plaintiff has 90 days to effect service if she intends to pursue the litigation. Teva says that a civil investigative demand it received on 2024-10-01 from the U.S. Attorney's office in Boston and the DOJ Civil Division, requesting information on manufacturing practices at its former Irvine, California facility (closed in 2022), arose from that complaint.

   U.S. District Court, District of Massachusetts · Status: pending

   Teva 10-Q for the quarter ended 2026-06-30

7. May 28, 2025Financing

   Teva subsidiaries issue euro and dollar senior notes to fund tender offer

   On 2025-05-28 three Teva finance subsidiaries issued senior notes: 1.0 billion euros of 4.125% notes due 2031, $500 million of 6.000% notes due 2032, and a series of 5.750% notes due 2030. Teva said it intends to use the net proceeds to fund a tender offer for a maximum combined aggregate purchase price of up to $2.25 billion (upsized from a previously announced cap of $2.0 billion), to pay fees and expenses, and, with any remainder, to repay outstanding debt.

   Teva 8-K filed 2025-05-28

8. Jan 15, 2025Litigation

   Teva challenges Medicare drug price negotiation rules; loses at district court

   On 2025-01-15 Teva sued the Centers for Medicare and Medicaid Services in federal court in Washington, DC, alleging that CMS's implementation of the Inflation Reduction Act drug price negotiation program is arbitrary and unconstitutional. The court granted CMS summary judgment on 2025-11-20. Teva appealed, the appeal was heard on 2026-05-05, and a decision remains pending according to the second quarter 2026 10-Q.

   U.S. District Court, District of Columbia · Status: appealed

   Teva 10-Q for the quarter ended 2026-06-30

9. Oct 31, 2024Regulatory

   European Commission fines Teva 462.6 million euros over alleged Copaxone anticompetitive practices

   On 2024-10-31 the European Commission issued a final decision alleging that Teva engaged in anticompetitive practices on Copaxone in certain member states, by filing and withdrawing certain divisional patents and by raising concerns about competitors' follow-on versions, and imposed a fine of 462.6 million euros. Teva filed an appeal with the General Court of the European Union in January 2025, which the 10-Q filed July 29, 2026 says remains pending. Teva has given the Commission surety guarantees covering the fine. Certain generic competitors have brought follow-on antitrust damages claims against Teva in Germany and the Netherlands, which have been stayed.

   General Court of the European Union · Status: appealed

   Teva 10-Q for the quarter ended 2026-06-30

Pipeline